In4Derm announces a strategic partnership with an innovation-driven NASDAQ listed biotech with a >$200m Option License Agreement for first-in-class BET bromodomain therapeutics pipeline.
In4Derm, an innovative biotech company developing novel therapeutics for inflammation and orphan indications, has today announced an Option and Licensing Agreement based around its pipeline of first-in-class, selective BET inhibitors.
The Strategic Partnership brings financial and development support to In4Derm, a University of Dundeespinout company, in addition to access to a novel pipeline for the partner. The partnership will work on the development of In4Derm’s pipeline assets and if successful, will lead to circa >$200m in milestone and royalties.
Tim Sparey, In4Derm CEO said “We are delighted to announce this deal.“
Both companies share the same vision for developing new therapeutics to treat high unmet needs in inflammation where millions of patients have no adequate treatment options. Our partnership will accelerate the development of In4Derm’s pipeline of oral BDII selective BET and topical BET compounds in major disease markets.
“The rapid progress of In4Derm from spinout in mid-2020 to seed round to strategic partnership in less than 12 months is testament to the commitment of the team and the support of its investors, the University of Dundee and Scottish Enterprise.”
Sunil Shah, CEO at o2h Ventures said: "This early discovery stage collaboration between In4Derm and the partner, will both provide the resources and speed up the time to provide novel drug therapeutics to patients. The first commercial deal for the company is a great platform for the team at In4Derm to develop novel therapeutic programmes”